YES1

Across TCGA pan-cancer cohorts, YES1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated YES1 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher YES1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated YES1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, HNSC, and GBM are the cancer types where YES1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.330	0.869	.006	21	view →
HNSC	DFS	Quartile	III,IV	0.636	0.888	.021	13	view →
GBM	DFS	Quartile	All	0.193	0.588	.001	10	view →
PDAC	DFS	Tertile	All	0.280	0.443	.015	8	view →
LSCC	OS	Median	III,IV	0.687	0.997	.006	8	view →
CCRCC	DFS	Quartile	II,III,IV	0.981	0.233	.030	8	view →
OV	DFS	Median	All	0.866	1.000	.036	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

YES1–LUAD (OS)

Open the LUAD breakdown →